Filed in archive
Corporate and Industrial News
, Drugs, Vaccines and Therapeutics
by ruth on June 14, 2006

Intercell recently announced favorable results for IC51 in Phase III clinical trials and the vaccine is currently under regulatory review in Europe with an orphan drug status.
Further details from Market Watch.
Tags:
vaccine
encephalitis
biotech
novartis
rights
japanese+encephalitis
vaccine+candidate
novartis+buys
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/24761
Mr Wong
Vote for Novartis Buys Rights to Intecell's Japanese Encephalitis Vaccine Candidate:
|
Rating: 9.50 out of 4 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







